The results of our clinical trial showed that among patients with acute myocardial infarction, which all patients were already receiving proven cardiovascular therapies, the level of IL-10 was significantly higher with the administration of colchicine five days late compared to the non-colchicine group. Here, IL10 is linked to myocardial infarction.